不同剂量瑞舒伐他汀治疗老年冠心病合并高脂血症的临床研究

目的探讨不同剂量瑞舒伐他汀治疗老年冠心病合并高脂血症的临床疗效。方法选取2011年7月—2013年12月来都江堰市中医医院就诊的老年冠心病合并高脂血症患者240例,随机分为辛伐他汀组,瑞舒伐他汀大、中、小剂量组,每组60例。辛伐他汀组患者晚餐后口服辛伐他汀片,20 mg/次,1次/d。瑞舒伐他汀大、中、小剂量组患者分别口服瑞舒伐他汀钙片20、10、5 mg/次,1次/d。两组均连续治疗6个月。观察各组的临床疗效,同时比较4组治疗前后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL)、低密度脂蛋白胆固醇(LDL)、颈动脉斑块的面积、颈内膜–中膜的厚度。结果治疗后,辛伐他汀组和瑞舒伐他汀大、中、小剂量组总有效率分别为63.33%、91.67%、76.67%、68.33%,大、中、小剂量组患者的总有效率明显高于辛伐他汀组;大剂量组的总有效率明显高于中、小剂量组,差异有统计学意义(P0.05)。治疗后,4组患者TG、TC、LDL、颈动脉斑块面积和颈内膜–中膜厚度均显著降低,HDL显著升高,同组治疗前后差异有统计学意义(P0.05);且大、中剂量组的改善程度优于辛伐他汀组,大剂量组的改善程度优于中、小剂量组,差异有统计学意义(P0.05)。结论瑞舒伐他汀治疗老年冠心病合并高脂血症患者具有较好的疗效,可有效改善患者的血脂水平,尤其是大剂量组疗效更佳。

Clinical study on different dosages of rosuvastatin in treatment of elderly coronary heart disease complicated with hyperlipidemia

Objective To investigate the effects and related mechanisms of different medications for treating dizziness induced by cerebral ischemia. Methods From September 2012 to February 2014, selected 120 patients with dizziness induced by cerebral ischemia were equally divided into treatment group and control group based on the principle of a random draw, the patients in control group received conventional therapy, on the basis of the patients in treatment group were treated with reteplase treatment. Results After treatment, the efficiencies in the treatment group and the control group were 95.0% and 83.3% with statistically significant difference between two groups (P < 0.05). The blood flow velocities of basilar artery and vertebral artery in two groups after treatment were significantly increased (P < 0.05), while the blood flow velocities of basilar artery and vertebral artery in the treatment group were significantly higher (P < 0.05). After treatment, the ABCD2 scores were significantly decreased (P < 0.05), but ABCD2 score in treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Cerebral ischemia-induced dizziness is more common in clinical practice, and reteplase adjuvant therapy can effectively reduce ABCD2 score, improve blood flow, thereby improve therapeutic efficacy.